Cemtrex enters the post-earnings window with a bruising revenue miss, a collapsing cost to borrow, and short interest that has been unwinding sharply — a combination that tells a more complicated story than either the bulls or bears would prefer.
The week's central tension is simple: shorts have been covering aggressively, yet the stock is still down 10% over the past five trading sessions and 34% in the past month.
Quarterly results landed after the bell on May 15, and they were not kind. Q2 EPS came in at $0.11, compared with $19.51 a year ago. Revenue fell to $18.1 million from $27.3 million. The stock closed at $0.80 on May 15 — a level that underlines the pressure the business is under even before the next earnings event on May 19.
Short sellers have been retreating, but the borrow market remains expensive. Short interest dropped to roughly 8.7% of the free float as of May 14 — down from a local peak near 34% in early April when the position was clearly under severe squeeze pressure. Over the past month alone, estimated short shares fell by more than 64%. That is a dramatic unwind. Availability in the lending market is now looser than it has been in weeks, and cost to borrow — while still elevated at 69.5% annually — has fallen sharply from the extraordinary levels of late April, when it briefly topped 340%. The borrow market is normalising, but it is still expensive by any conventional measure.
The ORTEX short score, at 70.5, remains high — ranking in the top tier of the universe — even as the raw short interest figure compresses. This divergence reflects how extreme the recent positioning cycle has been. The score peaked near 75 last week and has eased modestly, but a reading above 70 still points to meaningful bearish conviction relative to peers.
The earnings history reinforces the downside skew. The February 2026 Q1 release saw the stock fall 13.5% the next day and 20.3% over the following five sessions. The December 2025 print produced a 8.1% one-day drop and an 11.4% five-day decline. Every earnings event in the available history ended in a lower stock price. The next formal event is scheduled for May 19, just days away — though Thursday's Q2 release may have absorbed some of the immediate reaction.
Institutional ownership is thin and concentrated in passive and small allocators. Cambridge Investment Research added 189,850 shares as of March 31, the single largest disclosed holding. Vanguard and Geode hold nominal positions. Insider data is stale — the most recent disclosed trade is from June 2023 — so that angle adds nothing to the current read.
The question heading into next week is whether the cost-to-borrow normalisation continues alongside the short-interest unwind, or whether fresh supply of bearish conviction re-emerges in response to the deteriorating revenue trajectory.
See the live data behind this article on ORTEX.
Open CETX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
